Latest Clinical Trials
Recently developed TKIs such as ripretinib and avapritinib have the potential to change the treatment landscape of GIST.
Various studies have analyzed how to better diagnose gastrointestinal stromal tumors at the preoperative stage.
We explore how imatinib became the first-line therapy for metastatic GIST, and whether it should be discontinued in some circumstances.
We discuss current therapeutic strategies in targeting the PDGF/PDGFR signaling pathway in cancer research.
When diagnosed with a gastrointestinal stromal tumor (GIST) or any rare disease, the patient usually sees a doctor specializing in the treatment of that disease. Unfortunately, I live on a rock in the middle of the ocean, which makes finding the right doctor especially difficult.
Many cancer patients would disagree, but GIST cancer has been both the best and worst thing that has ever happened to me.
Three years ago, I heard one of the many things a cancer patient does not want to hear, “You have new growths. You’ve relapsed.” It was the first time I cried because of my cancer diagnosis, reality finally hit, and I was devastated. Relapsing with pediatric and wildtype (SDHA) gastrointestinal stromal tumor (GIST) was hard…
Deep learning is now used to detect disease or abnormalities from x-ray images and classify them into several disease types or severities in radiology.
It has been shown that radiomic features may be useful for predicting patient survival, treatment response, and metastatic potential of tumors.
When it comes to rare disorders, Israel—a New Jersey-sized nation of 9.3 million that’s made headlines this year for its highly successful coronavirus vaccination campaign—is clearly an emerging powerhouse.
Under COVID-19’s lingering shadow, the National Organization of Rare Disorders (NORD) has presented its 2021 Rare Impact Awards to 24 pharmaceutical firms, researchers, politicians, and nonprofit groups for their efforts over the past year on behalf of patients with such illnesses.
Rare Care Podcast
Advocating for People With Gastrointestinal Stromal Tumor: An interview with Peter Knox, senior research director at the Life Raft Group